Asundexian plus antiplatelet therapy reduces IS risk in patients with noncardioembolic stroke or high-risk transient ischemic attack.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results